Anti-EGFR mAbs have benefits in unresectable metachronous CRC metastases (in combination with FOLFIRI or irinotecan) in patients who are proven to have RAS wt disease and these data have informed the NCCN guidelines [4,14,31,32,33]. Here, EGFR is linked to colorectal carcinoma.